Swayampakula Ramakanth: Very good. And then the last question from me is on the prescriber front. It’s really great to hear that the cash-based prescribers are continuing to increase. I mean I can sit down and look at this, but because you said this could be a leading indicator, I want to ask you, what sort of a correlation are you seeing in terms of the growth of the prescribers and the revenue? I’m just trying to understand how to think through that growth because it can certainly just grow like crazy over this year, but I just want to understand how that growth could come through.
Dan Goldberger: Yes. We don’t have — I think the best way to look at it is it’s an 80-20 rule. Roughly 20% of those prescribers are generating 80% of the revenue. And so there are 2 ways to think about it. The first is that it’s just a numbers game, right? We have to sign up 100 to get 20 superstars. But what we’re also going to be doing in the back half of this year is trying to learn what are the characteristics of a high revenue Cash Pay practice? And how do we identify those characteristics and be more focused on the one hand in recruiting new customers? Or are there programs, marketing programs, for example, that we can use for the 80% of prescribers who aren’t generating a lot of revenue? So there’s still a lot of business model discovery ahead of us.
Swayampakula Ramakanth: Okay. Thank you very much. Thanks for taking all my questions. And good luck.
Dan Goldberger: Absolutely.
Operator: Thank you. Next question today is coming from Anthony Vendetti from Maxim Group. Your line is now live.
Anthony Vendetti: Yes, thanks. I was just wanting if you had an update — hey, how are you doing Dan, just an update on the ongoing clinical trials, any expectation for readouts in 2024?
Dan Goldberger: Yes. So the NOVIS trial in acute stroke is fully enrolled. I think the last patient last consult happened last month. And so I’m optimistic that we’ll see top line data in July, August kind of a time frame. And similarly, the Parkinson’s gait trial in Newcastle was fully enrolled at the end of last year. And so I’m hoping we see top line data in April or May. Actually, turning those into publications is going to take much longer. But that top line data in both indications will obviously impact our strategic thoughts about how do we leverage that data into an expanded indication and expanded label.
Anthony Vendetti: Okay. Great. And then just in terms of the VA, obviously, it’s one of your primary channels, how would you characterize current penetration? And I know there’s still an opportunity there, but what is the overall opportunity that remains with the VA?
Dan Goldberger: Sure. So we are — I measure penetration two ways. In terms of facilities, we are about 12% of the 1,300 facilities out there now. So still a lot of room to grow. But the better number to look at is the number of headache patients. I think there’s roughly 600,000 headache patients per year in the VA hospital system. And by that metric, we’re just barely 1% penetrated. Now as we make progress with PTSD, that dramatically increases the denominator, and of course, unfortunately, PTSD has a high prevalence in the VA hospital population, same with substance abuse, same with Parkinson’s and other neurological conditions. So as we add indications, our denominator gets bigger and our penetration gets smaller and opportunity gets bigger.
Anthony Vendetti: Okay, great. Thanks for the update. Appreciate it all the color
Dan Goldberger: Thanks.
Operator: Thanks. We reached the end of our question-and-answer session. I’d like to turn the floor back over to management for any further or closing comments.
Dan Goldberger: Thank you, operator. We appreciate everybody joining today’s call. I want to specifically say thank you to all of our employees who’ve been working tirelessly to deliver our amazing therapy to patients. Our team has done a great job of staying nimble, scaling the business and responding to the needs of our customers and health care providers alike, leading to the more than 60% compound annual growth over the last five years. I also want to thank the health care professionals and their patients for their loyal support of gammaCore therapy. Consumers, to their adoption of our Truvaga products as a tool to improve general wellness, and our champions at the Air Force and Army Special Forces. You all have a good evening.
Operator: Thank you. That does conclude today’s teleconference. You may disconnect your lines at this time, and have a wonderful day. We thank you for your participation today.
